These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225 [TBL] [Abstract][Full Text] [Related]
46. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma. Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090 [TBL] [Abstract][Full Text] [Related]
47. Distortions but not Definitive Peaks by Capillary Serum Protein Electrophoresis Indicate Monoclonal Gammopathy of Undetermined Significance rather than Multiple Myeloma. Liang CA; Zhang L; Segal G; Dasgupta A; Nguyen AND; Wahed A Ann Clin Lab Sci; 2020 Jan; 50(1):151-152. PubMed ID: 32161026 [TBL] [Abstract][Full Text] [Related]
48. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma. Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679 [TBL] [Abstract][Full Text] [Related]
49. A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Vallet S; Hoyle NR; Kyle RA; Podar K; Pecherstorfer M Leuk Lymphoma; 2018 Oct; 59(10):2431-2438. PubMed ID: 29345175 [TBL] [Abstract][Full Text] [Related]
50. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important. Berenson JR; Yellin O Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382 [TBL] [Abstract][Full Text] [Related]
52. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394 [TBL] [Abstract][Full Text] [Related]
53. [Unexpected symptoms of monoclonal gammopathy]. Smit PM; Abrahams AC; Schutgens RGE; Notermans NC; Minnema MC Ned Tijdschr Geneeskd; 2017; 161():D1741. PubMed ID: 29027517 [TBL] [Abstract][Full Text] [Related]
54. Quantitative Proteomic Analysis of Small and Large Extracellular Vesicles (EVs) Reveals Enrichment of Adhesion Proteins in Small EVs. Jimenez L; Yu H; McKenzie AJ; Franklin JL; Patton JG; Liu Q; Weaver AM J Proteome Res; 2019 Mar; 18(3):947-959. PubMed ID: 30608700 [TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871 [TBL] [Abstract][Full Text] [Related]
56. Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. Sproviero D; Gagliardi S; Zucca S; Arigoni M; Giannini M; Garofalo M; Olivero M; Dell'Orco M; Pansarasa O; Bernuzzi S; Avenali M; Cotta Ramusino M; Diamanti L; Minafra B; Perini G; Zangaglia R; Costa A; Ceroni M; Perrone-Bizzozero NI; Calogero RA; Cereda C Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800495 [TBL] [Abstract][Full Text] [Related]
57. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870 [TBL] [Abstract][Full Text] [Related]
58. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration. Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294 [TBL] [Abstract][Full Text] [Related]
59. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma. Scudla V; Petrova P; Minarik J; Pika T; Bacovsky J Neoplasma; 2011; 58(6):499-506. PubMed ID: 21895403 [TBL] [Abstract][Full Text] [Related]
60. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. Landgren O Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]